<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04114240</url>
  </required_header>
  <id_info>
    <org_study_id>2017-A03204-49</org_study_id>
    <nct_id>NCT04114240</nct_id>
  </id_info>
  <brief_title>French Study in Real Life Evaluating Xybilun</brief_title>
  <acronym>XY-FILM</acronym>
  <official_title>French Study in Real Life Evaluating Xybilun: Convenience and Erection Induction Related to a New Administration in Orodispersible Film</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoires Genévrier</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoires Genévrier</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Collecting Xybilun (Viagra's generic) efficacity, tolerance, convenience and patients/doctors
      satisfaction's data at different doses (50-75-100 mg), is the aim of the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design

      Population Patients without prior treatment with a first Xybilun prescription Patients
      already treated for who the treatment is remplaced by Xybilun

      Study perimeter 400 patients 50 investigators (sexologists, urologists)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 23, 2018</start_date>
  <completion_date type="Actual">April 26, 2019</completion_date>
  <primary_completion_date type="Actual">April 26, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patients who has never been treated for ED (group 1,2,3) : responder patients rate at V3 (IIEF-6 : international index of erectil function)</measure>
    <time_frame>3 months</time_frame>
    <description>Group 1: patient good responder if there is an increase of at least 2 points regarding score of IIEF-6; Group 2: patient good responder if there is an increase of at least 5 points regarding score of IIEF-6; Group 3: patient good responder if there is an increase of at least 7 points regarding score of IIEF-6;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patients with treatment substitution (group 4): satisfaction of Xybilun vs previous treatment at V3 (Likert scale 5 points : 1-Not satisfied at all, 2-not very satisfied, 3-nor satisfied nor unsatisfied, 4- satisfied, 5-very satisfied)</measure>
    <time_frame>3 months</time_frame>
    <description>Likert scale in 5 point evaluated at V3: &quot;Are you more satisfied regarding you previous treatment then your current treatment?&quot; Patient improved if his answer is &quot;satisfied&quot; (score 4) or &quot;very satisfied&quot; (score 5).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients who has never been treated for ED (group 1,2,3) : responder patients at V2 Month 1 (IIEF-6)</measure>
    <time_frame>1 month</time_frame>
    <description>score IIEF-6 (international index erectif function) score frome 0 to 30 : 22-25 ED mild, 11-21 ED moderate, 6-10 ED severe Group 1: patient good responder if there is an increase of at least 2 points regarding score of IIEF-6; Group 2: patient good responder if there is an increase of at least 5 points regarding score of IIEF-6; Group 3: patient good responder if there is an increase of at least 7 points regarding score of IIEF-6;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients who has never been treated for ED (group 1,2,3) : overall satisfaction at 1 month and 3 month</measure>
    <time_frame>1 month and 3 months</time_frame>
    <description>GAQ Global Assessment Questionnaire : 1 question &quot;does the treatment has ameliorate your erection&quot; Y/N</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients who has never been treated for ED (group 1,2,3) : Patient Xybilun and investigator satisfaction at V2 month 1 and V3 month 3</measure>
    <time_frame>1 month and 3 months</time_frame>
    <description>Likert scale (5 points) : 1 question : &quot;are you satisfied of Xybilun?&quot; (Likert scale 5 points : 1-Not satisfied at all, 2-not very satisfied, 3-nor satisfied nor unsatisfied, 4- satisfied, 5-very satisfied)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients who has never been treated for ED (group 1,2,3) : convenience at V2 month 1 and V3 month 3 (Likert scale)</measure>
    <time_frame>1 month and 3 months</time_frame>
    <description>Likert scale (5 points) : 1 question &quot;How convenient Xybilun is ?) (Likert scale 5 points : 1-Not convenient at all, 2-not very convenient, 3-nor convenient nor unconvenient, 4- convenient, 5-very convenient)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients who has never been treated for ED (group 1,2,3) : Partner satisfaction (Likert scale) at month 3</measure>
    <time_frame>3 months</time_frame>
    <description>Likert scale (5 points): (optional data) 1 question : &quot;are you satisfied of Xybilun?&quot; (Likert scale 5 points : 1-Not satisfied at all, 2-not very satisfied, 3-nor satisfied nor unsatisfied, 4- satisfied, 5-very satisfied)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with treatment substitution (group 4): International index of erectile function (IIEF) evolution (IIEF15)</measure>
    <time_frame>1 month and 3 months</time_frame>
    <description>IIEF15 international index of erectile function (15 questions scored from 0 to 5) ; score from 0 to 75 to evaluate globale erectil dysfunction (not used for classify the disfunction only to see the score evolution in the time)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with treatment substitution (group 4): satisfaction (patient/investigator) of previous treatment evaluated at V1 (Day 0) (Likert scale)</measure>
    <time_frame>Day 0</time_frame>
    <description>Likert scale (5 points) : &quot;Are you more satisfied regarding you previous treatment then your current treatment?&quot; scale 5 points : 1-Not satisfied at all, 2-not very satisfied, 3-nor satisfied nor unsatisfied, 4- satisfied, 5-very satisfied)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with treatment substitution (group 4): satisfaction of Xybilun (patient/investigator) at V2 month 1 and V3 month 3 (Likert scale)</measure>
    <time_frame>1 month and 3 months</time_frame>
    <description>Likert scale (5 points) : 1 question : &quot;are you satisfied of Xybilun?&quot; (Likert scale 5 points : 1-Not satisfied at all, 2-not very satisfied, 3-nor satisfied nor unsatisfied, 4- satisfied, 5-very satisfied)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with treatment substitution (group 4): convenience previous treatment at V1 (day 0) (Likert scale)</measure>
    <time_frame>Day 0</time_frame>
    <description>Likert scale (5 points) 1 question &quot;How convenient you previous treatment was ?) (Likert scale 5 points : 1-Not convenient at all, 2-not very convenient, 3-nor convenient nor unconvenient, 4- convenient, 5-very convenient)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with treatment substitution (group 4): convenience Xybilun (patient) at V2 month 1 and V3 month 3 (Likert scale)</measure>
    <time_frame>1 month and 3 months</time_frame>
    <description>Likert scale (5 points) 1 question &quot;How convenient Xybilun is ?) (Likert scale 5 points : 1-Not convenient at all, 2-not very convenient, 3-nor convenient nor unconvenient, 4- convenient, 5-very convenient)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with treatment substitution (group 4): Partner satisfaction at V3 month 3 (Likert scale)</measure>
    <time_frame>3 months</time_frame>
    <description>ikert scale (5 points): (optional data) 1 question : &quot;are you satisfied of Xybilun?&quot; (Likert scale 5 points : 1-Not satisfied at all, 2-not very satisfied, 3-nor satisfied nor unsatisfied, 4- satisfied, 5-very satisfied)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with treatment substitution (group 4): reasons of treatment substitution</measure>
    <time_frame>Day 0</time_frame>
    <description>1 question : &quot;reason of substitution : lack of efficacy, adverse event, bad taste, difficulty of taking, price elevated, ED healing, other (precise)&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with treatment substitution (group 4): efficacy of Xybilun comparing score IIEF-6 before/after treatment</measure>
    <time_frame>1 month and 3 months</time_frame>
    <description>score IIEF-6 (international index erectif function) score frome 0 to 30 : 22-25 ED mild, 11-21 ED moderate, 6-10 ED severe ED mild: responder if there is an increase of at least 2 points regarding score of IIEF-6; ED moderate: responder if there is an increase of at least 5 points regarding score of IIEF-6; ED severe: responder if there is an increase of at least 7 points regarding score of IIEF-6;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>1 month and 3 months</time_frame>
    <description>Adverse event : description of AE : open field, related or not to Xybilun, gravity scale (mild, moderate, severe, healththreatening)</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">105</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Xybilun: mild erectil dysfunction</arm_group_label>
    <description>Patient who has never been treated for his ED (erectil dysfunction), with mild ED (score IIEF-6 between 22 and 25) and begin treatment at 50 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xybilun: moderate erectil dysfunction</arm_group_label>
    <description>Patient who has never been treated for his ED (erectil dysfunction), with moderate ED (score IIEF-6 between 11 and 21) and begin treatment at 50 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xybilun: severe erectil dysfunction</arm_group_label>
    <description>Patient who has never been treated for his ED (erectil dysfunction), with severe ED (score between 6 and 10) and begin treatment at 50 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xybilun switch</arm_group_label>
    <description>Substitution dose to dose of previous treatment by Xybilun whatever the severity of ED.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xybilun</intervention_name>
    <description>Erectil dysfunction, Viagra generic (sildénafil)</description>
    <arm_group_label>Xybilun switch</arm_group_label>
    <arm_group_label>Xybilun: mild erectil dysfunction</arm_group_label>
    <arm_group_label>Xybilun: moderate erectil dysfunction</arm_group_label>
    <arm_group_label>Xybilun: severe erectil dysfunction</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Man suffering from all type of erectil dysfunction (light, moderate, severe).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; or equal 18 years

          -  Erectile dysfunction at V1 light (group 1), moderate (group 2), severe (group 3):
             IIEF-6 score between 6 and 25 (IIEF-6 questions 1-5 and question 15)

          -  More than 3 sexual intercourse

          -  First prescription of Xybilun (gr 1,2,3) or subtitution (gr 4)

          -  Information and non-opposition

        Exclusion Criteria:

          -  Sildénafil hypersensitivity

          -  Treatment with nitrogen oxide or guanylate cyclase

          -  Patient with sexual intercourse prohibited

          -  NOIANA

          -  Alpha-blocker during past 3 months

          -  Norvir

          -  Participation in an other clinical trial

          -  Patient unable to read properly an information sheet

          -  Patient under guardianship/curatorship
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DROUPY SD Stéphane, Urologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nîmes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Nîmes</name>
      <address>
        <city>Nantes</city>
        <state>Haute-Bretagne</state>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 6, 2018</study_first_submitted>
  <study_first_submitted_qc>October 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2019</study_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>erectil dysfunction</keyword>
  <keyword>sildenafil</keyword>
  <keyword>xybilun</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

